At a glance
A dual GIP and GLP-1 receptor agonist studied in metabolic care.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Trials assess weight and glycemic endpoints with defined formulations and schedules. Read these findings alongside adverse-event reporting and eligibility criteria.[4][8][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Tirzepatide.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 15 mg · 1 source tables
Standard / Gradual Approach (2 mL = 7.5 mg/mL)
| Phase | Weekly Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 33 units (0.33 mL) × 1 injection |
| Weeks 5–8 | 5 mg | 67 units (0.67 mL) × 1 injection |
| Weeks 9–12 | 7.5 mg | 100 units (1.0 mL) × 1 injection |
| Weeks 13–16 | 10 mg | 67 units (0.67 mL) × 2 injections |
Frequency: Inject once weekly subcutaneously on the same day each week[1][5]. For doses requiring multiple injections, administer consecutively at different sites. Dose increases occur every 4 weeks to minimize gastrointestinal side effects[1]. Higher doses (12.5–15 mg/week) may be used in subsequent phases if tolerated and clinically indicated.
Additional schedule context & duration
Concise summary of the once‑weekly regimen.
- Goal: Support glycemic control, weight management, and metabolic health through dual incretin receptor activation[2].
- Schedule: Weekly subcutaneous injection on the same day each week for 12–16+ weeks.
- Dose Range: 2.5–15 mg weekly with 4‑week titration intervals.
- Reconstitution: 2.0 mL per 15 mg vial (7.5 mg/mL) for manageable injection volumes.
- Storage: Lyophilized frozen; reconstituted refrigerated for up to 28 days.
Suggested weekly titration approach.
- Start: 2.5 mg once weekly for 4 weeks (initiation dose)[1].
- Escalate: Increase by 2.5 mg every 4 weeks as tolerated.
- Maintenance: 5–15 mg weekly based on response and tolerability.
- Frequency: Once per week (subcutaneous), same day each week.
- Timing: Any time of day; with or without food; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use within 28 days of reconstitution[6].
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); do not freeze reconstituted solution[6].
- Shelf life: Use reconstituted solution within 28 days[6].
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[7][9].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7][9].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
- Rotate sites systematically (abdomen avoiding 2‑inch radius around navel, outer thighs, upper arms) to avoid lipohypertrophy[7].
- Dispose of needles and syringes in a sharps container immediately after use[6].
Materials & quantity planning
Source materials checklist · 15 mg
Plan based on an 8–16 week protocol with gradual titration (once‑weekly dosing).
-
Peptide Vials (Tirzepatide, 15 mg each):
- 8 weeks (2.5→5 mg/wk): ~30 mg total ≈ 2 vials
- 12 weeks (2.5→7.5 mg/wk): ~60 mg total ≈ 4 vials
- 16 weeks (2.5→10 mg/wk): ~100 mg total ≈ 7 vials
-
Insulin Syringes (U‑100, 1 mL):
- 8 weeks: 8 syringes (1/week)
- 12 weeks: 12 syringes (1/week)
- 16 weeks: 20 syringes (1/week wks 1–12, 2/week wks 13–16)
-
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- 8 weeks (2 vials): 4 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 8 mL → 1 × 10 mL bottle
- 16 weeks (7 vials): 14 mL → 2 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each administration day.
- Per week: 2 swabs (1 injection day)
- 8 weeks: 16 swabs → recommend 1 × 100‑count box
- 12 weeks: 24 swabs → recommend 1 × 100‑count box
- 16 weeks: 32 swabs → recommend 1 × 100‑count box
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 15 mg per vial and 2 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 05
Public health resource
FDA Prescribing Information — Mounjaro (Tirzepatide) injection Prescribing Information. Eli Lilly and Company; 2022. (opens in a new tab)www.accessdata.fda.gov
Back to overview ↑ - 07
- 11
Public health resource
NCBI Bookshelf — Best practices for injection: asepsis, preparation, and administration techniques. (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 12
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route for drug delivery. (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.